- ISIN
- US0048901096
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Nov 15, 2022
Highlights
- Market Cap
- $64.20M
- Enterprise Value
- $33.71M
- EPS (TTM)
- -$2.00
- Gross Profit (TTM)
- $311.00K
- EBITDA (TTM)
- -$84.65M
- Year Range
- $1.20 - $3.56
- Target Price
- $21.83
- ROA (TTM)
- -71.65%
- ROE (TTM)
- -80.90%
- Avg. Volume (1M)
- 474K
- Avg. Volume Value (1M)
- $869.81K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ACRV Performance Chart
Acrivon Therapeutics Inc. Common Stock (ACRV) is down 37.8% since the beginning of the year. At $2 per share, ACRV is trading 57.9% below its 52-week high of $4.
Loading charts...
Compare this symbol against anything
Returns By Period
Acrivon Therapeutics Inc. Common Stock (ACRV) has returned -37.76% so far this year and 19.05% over the past 12 months.
Acrivon Therapeutics Inc. Common Stock
- 1D
- -1.32%
- 1M
- -12.79%
- 6M
- -16.20%
- YTD
- -37.76%
- 1Y
- 19.05%
- 3Y*
- -50.62%
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -44.55%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
ACRV Monthly Returns History
Based on dividend-adjusted daily data since Nov 15, 2022, ACRV's average daily return is -0.02%, while the average monthly return is -1.52%.
Historically, 44% of months were positive and 56% were negative. The best month was Mar 2024 with a return of +47.1%, while the worst month was Mar 2025 at -61.8%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 5 months.
On a daily basis, ACRV closed higher 46% of trading days. The best single day was Apr 9, 2024 with a return of +62.8%, while the worst single day was Mar 26, 2025 at -51.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -25.73% | -15.64% | -7.95% | 33.09% | -13.51% | 11.25% | -15.73% | -37.76% | |||||
| 2025 | 0.83% | -12.52% | -61.77% | -31.03% | -25.00% | 13.33% | 7.56% | 4.69% | 35.07% | 9.94% | 18.59% | 2.12% | -59.97% |
| 2024 | -25.81% | 33.15% | 47.12% | 27.13% | -15.07% | -24.87% | 44.48% | 13.25% | -26.24% | 14.29% | -5.25% | -20.58% | 22.36% |
| 2023 | 40.63% | 25.43% | -37.55% | -2.99% | -4.31% | 10.02% | -4.01% | -5.79% | -18.43% | -45.19% | -22.71% | 21.48% | -57.29% |
| 2022 | -3.75% | -10.35% | -13.71% |
Benchmark Metrics
Acrivon Therapeutics Inc. Common Stock has an annualized alpha of -29.34%, beta of 1.60, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since November 15, 2022.
- This stock participated in 313.90% of S&P 500 Index downside but only 14.36% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -29.34%
- Beta
- 1.60
- R²
- 0.05
- Upside Capture
- 14.36%
- Downside Capture
- 313.90%
Return for Risk
Risk / Return Rank
ACRV ranks 54 for risk / return — above 54% of stocks peers on PortfoliosLab. Its historical combined result is near the middle of the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Acrivon Therapeutics Inc. Common Stock (ACRV) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ACRV | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.23 | ||
| Sortino ratioReturn per unit of downside risk | -0.98 | ||
| Omega ratioGain probability vs. loss probability | 1.13 | 1.25 | -0.13 |
| Calmar ratioReturn relative to maximum drawdown | 0.30 | 2.00 | -1.70 |
| Martin ratioReturn relative to average drawdown | 0.52 | 8.49 | -7.97 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Acrivon Therapeutics Inc. Common Stock. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Acrivon Therapeutics Inc. Common Stock was 95.47%, occurring on May 30, 2025. The portfolio has not yet recovered.
The current Acrivon Therapeutics Inc. Common Stock drawdown is 93.53%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-95.47%May 2025 | 2y 3mo | — | 3y 5moFeb 2023 - now | 2025 selloff2025 |
-32.24%Dec 2022 | 1mo 11d | 1mo 6d | 2mo 17dNov 2022 - Feb 2023 | Bear market2022 |
-2.62%Feb 2023 | 1d | 3d | 4dFeb 2023 - Feb 2023 | — |
Drawdown Indicators
| ACRV | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.47% | -56.78% | -38.69% |
Max Drawdown (1Y)Largest decline over 1 year | -57.14% | -9.10% | -48.04% |
Max Drawdown (3Y)Largest decline over 3 years | -91.53% | -18.90% | -72.63% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -93.53% | -1.58% | -91.95% |
Average DrawdownAverage peak-to-trough decline | -71.30% | -10.70% | -60.60% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 33.25% | 2.14% | +31.11% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Acrivon Therapeutics Inc. Common Stock over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Acrivon Therapeutics Inc. Common Stock is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ACRV in comparison with other companies in the Biotechnology industry. Currently, ACRV has a P/B value of 0.6. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ACRV
Add Acrivon Therapeutics Inc. Common Stock to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ACRV